What is it about?
The current definition of HER2-low Breast cancer remains incomplete with low rates of interobserver concordance. This study aims to refine the HER2-low definition with emphasis on distinguishing HER2 score 0 from score 1+ to identify patients who are eligible for ADC.
Photo by National Cancer Institute on Unsplash
Why is it important?
After antibody-drug conjugate (Trastuzuman-deruxtecan) being approved for the treatment of HER2 low breast cancer patients, distinguishing patients that are HER2 IHC 1+ from IHC 0 became inevitable. This is the first study that refines the definition of HER2 1+ using HER2 RNA level and artificial neural network model with high interobserver concordance achieved.
Read the Original
This page is a summary of: Refining the definition of
‐low class in invasive breast cancer, Histopathology, September 2022, Wiley, DOI: 10.1111/his.14780.
You can read the full text:
The following have contributed to this page